Redirecting to https://apnews.com/press-release/globenewswire-mobile/blossomhill-therapeutics-to-present-preliminary-results-from-phase-1-dose-escalation-backfill-cohorts-in-phase-1-2-solara-trial-of-omni-egfr-inhibitor-bh-30643-in-advanced-egfr-mutant-nsclc-at-the-2026-asco-annual-meeting-5c8749eb603a8f4db99597c42c3bc44b